Galen announces exclusive licensing agreement with Almeda Pharmaceuticals AG

| Galen | News

Galen, the privately-owned pharmaceutical sales and marketing company, is pleased to announce a significant milestone in its global expansion strategy with the signing of an exclusive licensing deal with Almeda Pharmaceuticals AG.

The agreement provides Almeda Pharma with exclusive rights to license Galen’s latest product development PKU EASY Microtabs Plus, across several markets, including Ukraine, Moldova, Georgia, Armenia, Azerbaijan, and Kazakhstan.

Designed specifically for individuals with Phenylketonuria (PKU), Galen’s newest product PKU Easy Microtabs Plus, provides a phenylalanine-free protein substitute, enriched with vitamins, minerals, and the essential and non-essential amino acids, which replaces the requirement for a separate vitamin and minerals supplement.

PKU, a metabolic condition that prevents the breakdown of the amino acid phenylalanine, is a rare disease affecting 1 in 10,000 newborns in Europe.[i] If left untreated or inadequately managed, it can cause severe intellectual disability, epilepsy and behavioural problems.

Following the initial launch in Germany and the Nordics in October, Galen is planning a phased rollout of the product across other territories including the UK and the USA within the next 18 months. This expansion further increases access to more convenient care, ultimately enhancing the quality of life for those affected.

Speaking on the company’s announcement, Galen’s Head of Business Development Johnny McGaughey said: “We are thrilled to have signed a deal with Almeda Pharma for the licensing and distribution of Microtabs Plus in these important territories. This partnership aligns with our vision to make a positive impact on global healthcare by ensuring the availability of our products to a wider population and enhancing patient outcomes through like-minded partners”.

“We believe that everyone should have the right to access appropriate health care. Finding innovative solutions to improve access to medicines and treatments is the biggest challenge for many patients today. Through our commitment and daily efforts, we help people overcome this challenge and help them live longer and be healthier. Today we have made one more step forward in this direction.”, said Ala Tocarciuc, CEO of Almeda Pharmaceuticals AG.

More information on the partnership and Galen’s outlicensing opportunities can be found at   


[i] van Wegberg, A.M.J. et al. (2017) The complete European guidelines on phenylketonuria: Diagnosis and treatment - orphanet journal of rare diseases, BioMed Central. Available at: (Accessed: 16 January 2024).

Would you like to discuss how Galen can help you?

If you would like to explore how our expertise could add value to your product, or for an initial discussion about partnering with us, please contact our team.